{
    "address": "Scheelevagen 22",
    "city": "Lund",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W4R14V137",
    "description": "Guard Therapeutics International AB engages in the research, development, and commercialization of medical treatment and diagnosis based on alpha-1-microglobulin. The company is headquartered in Lund, Skane and currently employs 3 full-time employees. The company went IPO on 2013-04-03. The firm conducts development and commercialization of treatment and diagnostics based on the alpha-1-microglobulin (A1M) protein. The protein serves as a radical inhibitor, an antioxidant, a protector against free hemoglobin and a tissue repairer. A1M is a candidate for different therapeutic and diagnostic uses, such as alleviation of autoimmune diseases and stroke treatment. The firm works with the protein and conducts research at the Biomedical Center in Lund University, Sweden. The firm develops a drug for intravenous treatment of preeclampsia, a condition that can occur during pregnancy and can contribute to premature deliveries.",
    "employeeTotal": "3.0",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Biotechnology",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Biotechnology",
    "gsector": "Health Care",
    "gsubind": "Biotechnology",
    "ipo": "2013-04-03",
    "isin": "SE0009973357",
    "logo": "",
    "marketCapitalization": 302.4584,
    "naics": "Scientific Research and Development Services",
    "naicsNationalIndustry": "Research and Development in the Social Sciences and Humanities",
    "naicsSector": "Professional, Scientific, and Technical Services",
    "naicsSubsector": "Professional, Scientific, and Technical Services",
    "name": "Guard Therapeutics International AB (publ)",
    "phone": "46462865030.0",
    "sedol": "BYQMGT8",
    "shareOutstanding": 212.998874,
    "state": "SKANE",
    "ticker": "GUARD.ST",
    "weburl": "https://guardtherapeutics.com/"
}